TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04596384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Participate in a surgeon-only perioperative care program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Complete a functional assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear an actigraph

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Complete a nutritional assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05871255

Intervention type: OTHER
Intervention: Zantogin® Gel
Description: Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
Study: NCT05467683

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposure-Based Therapy
Description: Treatment will consist of 12 one-hour sessions, delivered over the course of 12 weeks. EBT will be delivered by trained and experienced license-eligible clinicians. The study clinician will develop a personalized assessment and treatment plan for each patient. Consistent with contemporary models of EBT, exposure practice aims to help patients reestablish a sense of safety around feared cues. Hence, exposure exercises are planned to ensure violation of threat expectancies. That is, exposure practice is deemed appropriate and effective if it allows the patient to learn that what they feared would happen does not happen. Practice will occur across relevant contexts both within and outside the session (i.e., homework) and clinicians will guide patients in processing practice to facilitate the consolidation of safety learning. To achieve these ends, study clinicians will use the manual Personalized Exposure Therapy: A Person-Centered Transdiagnostic Approach.
Study: NCT05864001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-C mobile app
Description: Digital coaching intervention for healthy lifestyle
Study: NCT06074991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musıc therapy
Description: Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
Study: NCT06168136

Intervention type: OTHER
Group type: OTHER
Intervention: protein diet
Description: this group of patients will receive high protein intake (target: 1.8 g protein/kg BW/d)

Intervention type: OTHER
Group type: OTHER
Intervention: Normal protein diet
Description: this group of patients will receive normal protein intake (target: 1.2 g protein/kg BW/d)
Study: NCT05531487

Intervention type: OTHER
Intervention: Questionnaire Survey
Description: All students received a 'QR code' link to the survey.
Study: NCT06322056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive control of SBP and intensive control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive control of SBP and standard control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of SBP and intensive control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of SBP and standard control of LDL-C
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
Study: NCT04144907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
Study: NCT05630768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate Sodium 35 MG [Actonel]
Description: Risendronate Sodium Tab. 35mg, orally, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Vitamin D combination
Description: orally, once daily for concomitant drug
Study: NCT06549556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule / Capsules per oral / once daily / 60 days duration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule / Capsules per oral / once daily / 60 days duration
Study: NCT05196425

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
Study: NCT06447818

Intervention type: OTHER
Intervention: Change in airway markers
Description: Mallampati and cormack lahane scores will be evaluated at the sixth postoperative month
Study: NCT04640844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: measuring the expression and function of lymphocyte A2A receptors.
Study: NCT06246617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci SP Surgical System for Single-Port Thoracic Surgeries
Description: Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
Study: NCT05334017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylometazoline 0,1%
Description: 1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine 4%
Description: 2 ml of 4% cocaine given as a nasal spray
Study: NCT05152927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parathyroid Eye (PTeye)
Description: Intraoperative Tool
Study: NCT05043090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: savolitinib
Description: Tablets : 3 × 200 mg tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Concentrate for solution for IV infusion : 1500 mg durvalumab every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: Capsules : 2 x 25mg capsules once daily 4 weeks on, 2 weeks off
Study: NCT04565041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
Study: NCT05054595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Management
Description: Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio-Recorded Mindfulness-Based Intervention
Description: Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Mindfulness-Based Intervention
Description: Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then guide them through a very brief (1 minute 30 second) mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
Study: NCT04977310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS
Description: Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery
Study: NCT06423612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POC urine assay informed enhanced ART adherence counselling for viral suppression
Description: Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their ART adherence with provision of enhanced ART adherence counseling for viral suppression.
Study: NCT06425484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral US TAP block
Description: epidural plus bilateral US guided TAP block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral US TAP block
Description: epidural plus bilateral US guided TAP block
Study: NCT06141044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Avoid surgical drainage
Description: Patients who undergo distal pancreatectomy, avoid placing a drain.
Study: NCT05713188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediSieve Magnetic Haemofiltration System
Description: The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
Study: NCT06219070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core straining
Description: The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
Study: NCT05870254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ExeRVIEM Program
Description: Virtual exercise based program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual center program
Description: Usual center cares

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual center program
Description: Usual center cares
Study: NCT05912387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg tablet once daily by mouth
Study: NCT05580744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional occupational therapy
Description: Motor training targeted to goals that are relevant to the functional needs of the patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy using a mirror box
Description: Mirror therapy using a mirror box

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality-based mirror therapy
Description: Augmented reality-based mirror therapy
Study: NCT04633707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjunctive bright white light therapy in the morning
Description: the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjunctive bright white light therapy in the afternoon
Description: the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: adjunctive dim red light therapy in the afternoon
Description: the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
Study: NCT05727384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: 5 mg, subcutaneous injection, every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg, subcutaneous injection, every 4 weeks for 24 weeks
Study: NCT06069206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T2Bacteria® Panel (direct-from-blood testing)
Description: Providers will be prompted to order the T2Bacteria® Panel (direct-from-blood testing) and accompanying communications regarding panel results will be delivered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard blood cultures.
Study: NCT05546554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 5 mg (and up to 20 mg) Suvorexant given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 5 mg (and up to 20 mg) Suvorexant given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo given orally
Study: NCT05103228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Alfa
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
Study: NCT05461482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-procedural consultation and audiovisual tools
Description: In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
Study: NCT05474586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collavant n2 40 mg/day
Description: 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine hydrochloride & Chondroitin sulfate
Description: 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: 2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
Study: NCT05508750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Infant Formula
Description: New infant formula fed daily ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Infant Formula
Description: Commercially available infant formula fed daily ad libitum
Study: NCT05227157

Intervention type: OTHER
Intervention: swab with iron sulfate solution
Description: measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
Study: NCT05398510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2010 injection
Description: Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-2010 injection placebo
Description: Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
Study: NCT04179448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAMRI
Description: Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STA
Description: Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
Study: NCT04924504

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT05886582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine Transdermal System [Neupro]
Description: Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study: NCT05045326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation program
Description: Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Brief Counselling
Description: Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
Study: NCT05932004

Intervention type: OTHER
Group type: OTHER
Intervention: Reformer pilates exercise
Description: The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list

Intervention type: OTHER
Group type: OTHER
Intervention: Reformer pilates exercise
Description: The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list
Study: NCT06073236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The healthy day-project
Description: The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
Study: NCT05335148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral colchicine(0.6 mg) once a day
Description: The standard of care arm will receive a placebo colchicine pill once a day